Mikolaj Rafal Kowal

Dr. Mikolaj Rafal Kowal

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2022 in Colorectal Disease
Verified
Journal Article
Open access
MKMikolaj Rafal Kowal
Mikolaj Rafal Kowal
FDFrancesca Douglas
Francesca Douglas
DJDavid Jayne
David Jayne
DMDavid Meads
David Meads
Aim: The global burden of colorectal cancer (CRC) is set to increase by 60% by 2030. An aging population and increasing treatment complexity add difficulties for patients and clinicians in CRC management. Patient preferences can be investigated using attribute‐based stated preference (AbSP) techniques to explore trade‐offs between different treatments. These techniques include discrete‐choice experiments (DCEs), conjoint analysis and time‐trade off (TTO) methods. This systematic review with a narrative synthesis aimed to determine the use and design of AbSP studies in CRC treatment and to identify patient choice themes.Methods: The searches were performed using MEDLINE, Embase, PsycInfo and Cochrane Library in March 2021. All manuscripts featuring the use of AbSP techniques in CRC treatment were included. Data synthesis was performed using a narrative approach.Results: The search strategy returned 271 articles. Eighteen AbSP studies were included featuring 1890 patients and 296 clinicians. AbSP techniques compromised DCE (38.9%, n = 7), TTO (38.9%, n = 7) and conjoint analysis (22.2%, n = 4). Eleven studies (61.1%) involved piloting of tasks and the average task completion rate was 75%. CRC treatments included chemotherapy (33%, n = 6), combined treatments (33%, n = 6), surgery (17%, n = 3), targeted therapy (11%, n = 2) and radiotherapy (6%, n = 1). The most examined domain was physical health, investigated with 49 (59.8%) attributes.Conclusions: Life expectancy was the main attribute in chemotherapy treatment. With surgery, patients were willing to trade life‐expectancy to avoid adverse outcomes or a permanent stoma. Communication skills, treatment cost, and clinicians' views were important attributes for patients in cancer services. Further research in the elderly population, and other quality of life domains, are needed to deliver patient‐centred CRC care.

20 April 2022 in BJS Open
Verified
Journal Article
Open access
PDF file
JBJoshua Burke
Joshua Burke
KSKunal Shetty
Kunal Shetty
OTOwen Thomas
Owen Thomas
MKMikolaj Rafal Kowal
Mikolaj Rafal Kowal
AQAaron Quyn
Aaron Quyn
PSPeter Sagar
Peter Sagar
Tumours of the retrorectal space are uncommon, pathologically heterogeneous, and difficult to diagnose, with ongoing controversy over their surgical management. The aim of this study was to evaluate the surgical management of a consecutive series of patients who had undergone excision of primary retrorectal tumours (PRRTs) at a tertiary referral centre. Patients were identified from a prospectively maintained database between 1 March 2001 and 1 August 2021. Electronic patient records were reviewed for demographics, preoperative imaging, operative details, histology, and follow-up. A chi-squared test was used to assess the statistical significance of findings. A total of 144 patients were included in the study. Of these, 103 patients were female (71.5 per cent), 46 patients (31.9 per cent) presented incidentally, and 99 of the patients had tumours located below S3 (68.7 per cent). Overall, 76 patients underwent a transperineal approach (52.7 per cent) with the most common findings of a benign tailgut cyst occurring in 59 (40.9 per cent) of cases. Preoperative MRI predicted urovascular and pelvic sidewall involvement assessed intraoperatively with a sensitivity of 83.3 and 90 per cent and a specificity of 98.1 and 98 per cent respectively. Risk of malignancy in solid tumours was 31.4 versus 8.8 per cent in cystic tumours (relative risk 3.5, 95 per cent c.i. 1.6 to 7.6, P < 0.001). Major complications (Clavien–Dindo grade III and above) occurred in eight patients (5.6 per cent) and all-cause long-term mortality was 4.8 per cent (seven patients). PRRTs can be safely excised with minimal complications in specialized centres by surgical teams with the relevant expertise. This study questions the conservative management of cystic tumours and given the risk of solid tumour malignancy, supports surgical management.

Verified
Journal Article
Open access
PDF file
MKMikolaj Rafal Kowal
Mikolaj Rafal Kowal
MIMohammed Ibrahim
Mohammed Ibrahim
AMAndré L. Mihaljević
André L. Mihaljević
PKPhilipp Kron
Philipp Kron
PLPeter Lodge
Peter Lodge
Surgery remains a healthcare intervention with significant risks for patients. Novel technologies can now enhance the peri-operative workflow, with artificial intelligence (AI) and extended reality (XR) to assist with pre-operative planning. This review focuses on innovation in AI, XR and imaging for hepato-biliary surgery planning. The clinical challenges in hepato-biliary surgery arise from heterogeneity of clinical presentations, the need for multiple imaging modalities and highly variable local anatomy. AI-based models have been developed for risk prediction and multi-disciplinary tumor (MDT) board meetings. The future could involve an on-demand and highly accurate AI-powered decision tool for hepato-biliary surgery, assisting the surgeon to make the most informed decision on the treatment plan, conferring the best possible outcome for individual patients. Advances in AI can also be used to automate image interpretation and 3D modelling, enabling fast and accurate 3D reconstructions of patient anatomy. Surgical navigation systems utilizing XR are already in development, showing an early signal towards improved patient outcomes when used for hepato-biliary surgery. Live visualization of hepato-biliary anatomy in the operating theatre is likely to improve operative safety and performance. The technological advances in AI and XR provide new applications in pre-operative planning with potential for patient benefit. Their use in surgical simulation could accelerate learning curves for surgeons in training. Future research must focus on standardization of AI and XR study reporting, robust databases that are ethically and data protection-compliant, and development of inter-disciplinary tools for various healthcare applications and systems.

9 November 2021 in Scandinavian Journal of Surgery
Verified
Journal Article
Open access
PDF file
MKMikolaj Rafal Kowal
Mikolaj Rafal Kowal
WBWilliam Bolton
William Bolton
BDBernard Van Duren
Bernard Van Duren
JBJoshua Burke
Joshua Burke
DJDavid Jayne
David Jayne
Background and objective: Surgical drains are widely utilized in hepatopancreaticobiliary surgery to prevent intra-abdominal collections and identify postoperative complications. Surgical drain monitoring ranges from simple-output measurements to specific analysis for constituents such as amylase. This systematic review aimed to determine whether surgical drain monitoring can detect postoperative complications and impact on patient outcomes. Methods: A systematic review was performed, and the following databases searched between 02/03/20 and 26/04/20: MEDLINE, EMBASE, The Cochrane Library, and Clinicaltrials.gov. All studies describing surgical drain monitoring of output and content in adult patients undergoing hepatopancreaticobiliary surgery were considered. Other invasive methods of intra-abdominal sampling were excluded. Results: The search returned 403 articles. Following abstract review, 390 were excluded and 13 articles were included for full review. The studies were classified according to speciality and featured 11 pancreatic surgery and 2 hepatobiliary surgery studies with a total sample of 3262 patients. Postoperative monitoring of drain amylase detected pancreatic fistula formation and drain bilirubin testing facilitated bile leak detection. Both methods enabled early drain removal. Improved patient outcomes were observed through decreased incidence of postoperative complications (pancreatic fistulas, intra-abdominal infections, and surgical-site infections), length of stay, and mortality rate. Isolated monitoring of drain output did not confer any clinical benefits. Conclusions: Surgical drain monitoring has advantages in the postoperative care for selected patients undergoing hepatopancreaticobiliary surgery. Enhanced surgical drain monitoring involving the testing of drain amylase and bilirubin improves the detection of complications in the immediate postoperative period.

27 January 2026 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
ADAlexios Dosis
Alexios Dosis
ASAron Berger Syversen
Aron Berger Syversen
MKMikolaj Rafal Kowal
Mikolaj Rafal Kowal
DGDaniel Grant
Daniel Grant
JTJim Tiernan
Jim Tiernan
DJDavid Jayne
David Jayne
Background: Current methods of cardiorespiratory fitness (CRF) assessment may discriminate against frail individuals who are challenged to perform a maximal cardiopulmonary exercise test. CRF estimations from free-living wearable data, captured over extended time periods, may offer a more representative assessment and increase usability in clinical settings. Objective: This study aimed to review current evidence behind this novel concept and evaluate the performance and quality of models developed to estimate CRF from free-living, unsupervised data. Methods: Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we systematically searched 4 databases (MEDLINE, Embase, Scopus, and arXiv) for studies reporting the development of models to estimate CRF from continuous free-living wearable data. Studies conducted entirely under controlled laboratory conditions were excluded. Performance metrics were combined in a meta-correlation analysis using a random-effects model and Fisher Z transformation. Results: Of 1848 papers screened, 18 met the eligibility criteria, with a total of 31,072 participants. The weighted mean age was 46.9 (SD 1.46) years. Multiple computational techniques were used, with 8 studies employing more advanced machine learning models. The meta-correlation analysis revealed a pooled overall estimate of 0.83 with a 95% CI 0.77‐0.88. The I 2 test indicated high heterogeneity at 97%. Risk of bias assessment found most concerns in the data analysis domain, with studies often lacking clarity around the data handling process. Conclusions: A promising preliminary agreement between CRF predictions and measured values was noted. However, no definite conclusions can be drawn for clinical implementation due to high heterogeneity among the included studies and lack of external validation. Nonetheless, continuous data streams appear to be a valuable resource that could lead to a step change in how we measure and monitor CRF.

7 October 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MKMikolaj Rafal Kowal
Mikolaj Rafal Kowal
ASAndrew Smith
Andrew Smith
SPSanjay Pandanaboyana
Sanjay Pandanaboyana
SPSamir Pathak
Samir Pathak
Pancreatic ductal adenocarcinoma (PDAC) has poor survival outcomes. The main reasons include late presentation, resulting in only 20% of patients being eligible for surgery, and poor response to chemotherapy, secondary to the challenging tumour biology (1,2). For patients undergoing surgery, the local anatomy and invasiveness of PDAC results in high operative risks, with morbidity and mortality estimated at 50-70% and 2-8%, respectively (3,4). The incidence of PDAC is rising, making it the fourth leading cause of death in the United States (5). It is imperative to prioritise PDAC research. Technological advances may improve patient outcomes through early detection and optimisation of treatments. The editorial highlights the latest technological advances in PDAC and identifies areas for research.Technological breakthroughs enabling early detection of PDAC were described in a review on liquid biopsy (6). This sampling method uses biomarkers such as circulating tumour DNA (ctDNA) and extracellular vesicles (EVs). Liquid biopsy is exciting due to its non-invasive, real-time and repeatable properties. Recent advances in methylation analysis, detecting epigenetic reprogramming in early tumorigenesis, have improved the detection of PDAC using ctDNA. A meta-analysis performed in 2019 showed sensitivity and specificity rates of 70% and 86% respectively. Another biomarker showing promise are EVs, with one study showing high sensitivity and specificity rates of 99% and 82% respectively. The current accuracy of liquid biopsy across all methods for PDAC was investigated in a meta-analysis (7). They concluded that liquid biopsy using biomarkers such as ctDNA was less accurate than CA19-9 for PDAC detection. However, ctDNA was associated with worse survival, making it a useful prognostication tool. Further research utilising multiple biomarkers may increase the accuracy in PDAC detection.Advances in neoadjuvant chemotherapy regimens are enabling surgical treatment for patients with locally advanced PDAC. Zhang et al. documented the case of a patient with a locally advanced PDAC (8). Following six cycles of GEM-NabP chemotherapy the patient underwent surgery, with histology confirming near-complete response. Successes such as this are often attributed to favourable biology, but standardisation of neoadjuvant regimens may improve overall outcomes. Further improvements in neoadjuvant treatments are seen in combination with immunotherapy. Lu and colleagues published a case report of combined neoadjuvant treatment using a programmed cell death protein-1 inhibitor and chemoradiotherapy (9). Following neoadjuvant treatment for a locally advanced PDAC, the patient underwent a pylorus-preserving pancreaticoduodenectomy (PPPD) with histology showing a pathologic complete response.Further data is also showing the benefit of established adjuvant chemotherapy regimens. A retrospective cohort study by Choi and colleagues analysed outcomes for patients who received adjuvant chemotherapy for locally advanced PDAC (10). They showed that 5-fluorouracil-based regimens resulted in favourable survival. New advances have also been made in the delivery of chemotherapy. Cao et al. performed a meta-analysis of regional intra-arterial chemotherapy (RIAC) compared with systemic treatment (11). RIAC has been developed recently and trialled in PDAC due to its ability to deliver high concentrations locally, while maintaining low systemic drug levels. Their analysis concluded that patients who received RIAC had a higher rate of partial remission and fewer complications. The studies highlighted show progress within chemotherapy and immunotherapy. There is an urgent need for standardisation of regimens, combination therapy and drug delivery.Technological advances in radiotherapy (RT) for PDAC were highlighted in a review article by Malla et al (12). Despite the ability to convert borderline resectable cases to surgical resection, up to a third of patients can die during RT from disease progression. Advances in Stereotactic Body Radiation Therapy (SBRT) and hypofractionation enable the delivery of biologically effective doses with reduced toxicity to surrounding tissues. Specifically, innovation in magnetic resonance-guided on-table adaptive RT is enabling this. A recent phase two trial demonstrated reduced incidence of acute grade 3+ gastrointestinal toxicity at 90 days post treatment. New trials are also being conducted on nanoparticles to enhance RT delivery. Hafnium oxide nanoparticles NBTXR3 are activated by RT to improve radiation-induced abscopal effects. These technologies are likely to improve the effects of neoadjuvant RT for patients with PDAC. Healthcare professionals will have the tools to deliver highly effective doses of RT without the tissue toxicity that currently limits the treatment potential of this therapy.For patients eligible for surgery, advances in surgical technology are improving outcomes. The uptake of minimally invasive surgery (MIS) for PDAC was analysed by Yan et al. in their metaanalysis of laparoscopic versus open PPPD (13). The 39 studies demonstrated reduced morbidity, length of stay (LOS), blood loss, delayed gastric emptying as well as higher R0 rates in laparoscopic PPPD. The authors importantly highlight that only four randomised controlled studies (RCTs) were included. Two of these were multi-centre and all non-randomised trials were retrospective, showing a need for standardised high-quality surgical trials. The advances of MIS have since been taken further with the advent of robotic surgery. The recently published RCT concerning PDAC has demonstrated safety of the robotic approach for PPPD (14). Novel surgical devices are also prospects for improving patient outcomes. Sheen and colleagues compared the AEON™ endovascular stapler with traditional devices for laparoscopic distal pancreatectomy in 58 patients (15). Their analysis of using AEON™, characterised by uniform staple...